Evaluation of Metamemory Using a Semantic Construction Strategy in Patients With Schizophrenia

NCT02932059 | Unknown

• 2 other identifiers: CHU-02802016-A00944-47
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the respective roles of aging and schizophrenia in the regulation of metamemory using a sentence construction strategy. 4 groups will be necessary to comparison: Adult patients (18-45 years) Adult controls (18-45 years) Aged patients (≥ 55 years) Aged controls (≥ 55 years) The effects of age and the disease could lead to interaction in regulating metamemory. The effect of age would be aggravated by the disease.

Conditions

Schizophrenia; Aging

Keywords

Metamemory; Schizophrenia; Aging; Learning; Judgement of learning; Sentence construction strategy

Outcome Measures

Primary Outcomes (1)

• difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) in the sentence construction strategy

  the 4 groups of participants formed by the case-control study in two age strata value their judgments of learning for each pair of words using a 5 point scale (0%, 25%, 50%, 75%, 100%) in the sentence construction strategy. Four groups are : * Adult schizophrenic patients (18-45 years) * Aged patients with schizophrenia (≥ 55 years) * Adults controls (18-45 years) * Aged controls (≥ 55 years)

  at day 1

Secondary Outcomes (1)

• difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) between sentence construction and reading strategies.

  at day 1

Study Arms (4)

Adult schizophrenic patients (18-45 years)

EXPERIMENTAL

4 groups formed by the case-control study in two age strata

Behavioral: Metamemory

Aged patients with schizophrenia (≥ 55 years)

EXPERIMENTAL

4 groups formed by the case-control study in two age strata

Behavioral: Metamemory

Adults controls (18-45 years)

EXPERIMENTAL

4 groups formed by the case-control study in two age strata

Behavioral: Metamemory

Aged Controls (≥ 55 years)

EXPERIMENTAL

4 groups formed by the case-control study in two age strata

Behavioral: Metamemory

Interventions

Metamemory BEHAVIORAL

Metamemory evaluation using a sentence construction strategy

Adult schizophrenic patients (18-45 years); Adults controls (18-45 years); Aged Controls (≥ 55 years); Aged patients with schizophrenia (≥ 55 years)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• For both:
• MMSE score greater than or equal to,
• if no grade
• if study certificate or CAP or college without patent
• if patent or school without the tray
• or more when bin
• IQ ≥ 75 (fNART)
• Age: between 18 and 45 years for adults, and 55 and older for older,
• For patients :
• DSM-5 criteria of schizophrenia
• Adult patients (\<45 years) will be matched to elderly patients (\> 55 years) gender and IQ,
• Patients followed as outpatients,
• Age of onset of the disease less than 40 years,
• Patients whose disease has stabilized: no changes psychotropic treatment for at least 1 month
• Not more of a benzodiazepine,

You may not qualify if:

• For patients :
• Any other comorbid psychiatric diagnosis of Axis I DSM-5
• Extrapyramidal syndrome or tardive dyskinesia (AIMS score \<2 BARS score \<2 and score Simpson and Angus \<3)
• Calgary depression scale ≥ 6
• Current or past addiction to all toxic substances (including alcohol and cannabis) except tobacco.
• Current or past use of all toxic consumption (excluding alcohol, tobacco and cannabis).
• Use of alcohol or cannabis before the age of 15 years
• Alcohol abuse in the past 6 months.
• Cannabis abuse in the past 6 months and cannabis use in the last 3 months.
• Patients with impaired vision or hearing preventing the realization of the tests.
• For controls:
• Any psychiatric diagnosis according to DSM-5, including addictions (excluding tobacco)
• Score HADS Anxiety ≥ 8 and Depression ≥ 8
• SCL90R: global severity score GSI\> 0.33 for women and\> 0.27 for men, or score diversity PST symptoms\> 18.49 for men and\> 21.97 for women or score of degree of discomfort PSDI\> 1.27 for men and\> 1.3 for women, scoring in the subscale Psychotic Features\> 0.
• Presence of a personality disorder at PDQ4 +

Sponsors & Collaborators

• University Hospital, Clermont-Ferrand: lead
• LAPSCO, Psychology University, Blaise Pascal University, Clermont-Ferrand.: collaborator

Study Sites (1)

CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France

RECRUITING

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Study Officials

• Isabelle JALENQUES

  CHU Clermont-Ferrrand

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Patrick LACARIN

CONTACT

04 73 75 11 95; placarin@chu-clermontferrand.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 4, 2016
• First Posted: October 13, 2016
• Study Start: June 19, 2017
• Primary Completion: February 1, 2020
• Study Completion: September 1, 2020
• Last Updated: July 27, 2017

Record last verified: 2016-10

Locations

FR (1)